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INTRODUCTION
Shiragami and colleagues [1] have presented a
cost-effectiveness model of the use of routine
pneumococcal vaccination in infants in Japan
using the 10-valent pneumococcal conjugate
vaccine (PCV10) and the 13-valent
pneumococcal conjugate vaccine (PCV13). In
this analysis, the authors concluded that the
routine use of PCV10 was more cost-effective
than PCV13. While the analysis applies
modeling methodologies that are sound, many
of the assumptions presented in the paper are
inconsistent with current published scientific
evidence, specifically those regarding PCV13
effectiveness against serotype 3, PCV10
effectiveness against pneumonia, PCV10
effectiveness against otitis media, PCV10 cross-
protection against serotypes not contained in
the vaccine (serotypes 6 and 19A), and herd
effects. We challenge these assumptions using
previously conducted studies and data in the
public domain.
Both vaccines received approvals (PCV10
and PCV13 in the European Union in 2009
and PCV13 in the United States in 2010) based
on immunologic criteria; no efficacy studies
formed the licensure criteria. Therefore, early
cost-effectiveness evaluations required
extrapolation of immunogenicity to clinical
effectiveness. We discussed the criteria under
which appropriate assumptions could be
formulated in a review paper [2]. In
subsequent years, several efficacy and
effectiveness evaluations have been conducted
around the world to fully evaluate both
vaccines. PCV10 data have been analyzed in 2
randomized controlled trials [3, 4], and PCV13
data have largely come from studies assessing
the effectiveness of vaccination after
introduction in national immunization
programs initiated following the transition
from the 7-valent pneumococcal conjugate
vaccine (PCV7) to PCV13. Since the
introduction of PCV13 in countries having a
national immunization program, there has been
a decline in vaccine-type invasive and
noninvasive pneumococcal infections in
children and adults (via herd effect) as well as
a reduction of nasopharyngeal carriage after the
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The protection of PCV13 against invasive
pneumococcal disease caused by serotype 3 is
assumed by Shiragami and colleagues to be
0.00%, largely on the basis of the authors’
selection of outdated Joint Committee on
Vaccination and Immunisation (JCVI) minutes
[15]. Themost recent JCVIminutes have included
a revised statement indicating that the number of
serotype 3 cases has declined in the United
Kingdom following the introduction of PCV13
in the UK National Immunisation Program [16].
In other countries with robust surveillance
systems, positive point estimates for serotype 3
have been presented [13, 17, 18]. Although it is
true that positive point estimates for serotype 3
effectiveness took longer to reach statistical
significance [13], it is clear that PCV13 cannot
be considered ineffective against serotype 3.
EFFECTIVENESS AGAINST
PNEUMONIA
Because of high incidence and expenditures,
pneumonia is a significant driver of the costs of
pneumococcal infections. Assuming that
PCV10 and PCV13 have equal effectiveness is
inconsistent with the current evidence that
serotype coverage plays an important role in
the potentially preventable burden of disease.
We agree with the authors that the clinical trial
results of PCV7 and PCV10 against X-ray-
confirmed pneumonia were similar; however,
comparisons between the COMPAS study
(PCV10 [19]) and the Northern California
Kaiser Permanente study (PCV7 [20]) are
historical. At the present time, the comparison
needs to be made against PCV13, a vaccine with
6 additional serotypes compared with PCV7. In
the United States, for example, after a 43%
nationwide decline in hospitalizations for all-
cause pneumonia in children\2 years of age
was achieved with PCV7, data from Tennessee
showed an additional reduction of 27%
following the introduction of PCV13 [10]. In
Sweden, where both PCV10 and PCV13 are used
in different county councils, the number of
cases of hospitalized pneumonia significantly
decreased in county councils that made a
transition from PCV7 to PCV13; during the
same time period, no additional reductions
were observed in county councils that
switched from PCV7 to PCV10 [7]. The
observed differences between PCV10 and
PCV13 reached statistical significance [7].
Effectiveness data from France [5], Nicaragua
[6], and Uruguay [21, 22] confirm additional
benefits in the PCV13 post-vaccination period
compared with the pre-vaccination period, not
only in the incidence of uncomplicated
pneumonia, but also in the incidence of cases
resulting in hospitalization or complicated with
pleural effusion.
Basedon these recent publications and the fact
that protection against disease is based on the
serotypes contained in the vaccine, we believe
that using serotype coverage proportional to the
individual effectiveness of PCV10 and PCV13
would have been more appropriate.
EFFECTIVENESS AGAINST OTITIS
MEDIA
Farkouh et al. [2] described in detail the issues
specific to acute otitis media (AOM) with
models of PCV cost-effectiveness. The
incorrect assumptions used in the model by
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Shiragami and colleagues, specifically the
hypothetical effect of the vaccine against
disease caused by non-typeable Haemophilus
influenzae (NTHi) and cross-protection against
the 6A and 19A serotypes, result in an
overstatement of the effectiveness of PCV10
against acute otitis media. After 5 years of use,
no evidence of effectiveness against NTHi has
emerged from any country that has evaluated
PCV10. The inclusion of the Pneumococcal
Otitis Efficacy Trial (POET) from the Czech
Republic in the model of Shiragami and
colleagues is inappropriate because it evaluated
a markedly different vaccine formulation that
was never brought to market and it used a
highly selective population [23, 24].
Furthermore, the confidence intervals observed
for NTHi were wide, and methodological flaws
were observed, such as the extraordinarily low
number of otitis media cases and the low
number of bacteriologically confirmed otitis
media cases [25].
Two studies of all-cause AOM conducted in
Finland, one assessing PCV7 and the other
assessing PCV10, each found nearly the same
reduction in AOM, supporting that there was no
added benefit in reduction of all-cause AOM
with PCV10 [26, 27]. Since the United States
transitioned from PCV7 to PCV13, an
additional reduction in all-cause AOM has
been reported in children\2 years of age,
supporting an incremental benefit of PCV13 in
the reduction of AOM consistent with its
broader serotype coverage [28]. As highlighted
previously [2, 29], and again in the model of
Shiragami and colleagues, AOM is erroneously
responsible for the majority of modeled cost
differences reported between the 2 vaccines.
Based on the available information and the fact
that protection against disease is based on the
serotypes contained in the vaccine, we believe
that using an effectiveness analysis that is
proportional for the serotype coverage of





Early studies relied on PCV7 data to extrapolate
effectiveness of the higher valent vaccines.
However, after 5 years of use, a vaccine should
be able to support assumptions with evidence.
Considering that PCV7 and PCV10 are
manufactured using different carrier proteins
and conjugation chemistries, making
extrapolations between these vaccines is
questionable. Therefore, it is inappropriate for
Shiragami and colleagues to reference a US
study of PCV7 to support the contention that
the serotype 6B antigen in PCV10 provides
protection against serotype 6A. After 5 years of
use, there should be sufficient data for PCV10 to
support such a claim of protection. If these data
are still not present, it is inappropriate to
assume cross-protection. Evidence regarding
the lack of cross-protection of PCV10 against
serotype 6A is currently available [30].
More importantly, the issue of serotype 19A
cross-protection is critical in Japan because
serotype 19A currently represents 45% of
pneumococcal serotype isolates [31], not the
25% referenced by Shiragami and colleagues. It
is widely known that, during the PCV7 era,
serotype 19A emerged as a dominant serotype
globally. To support the claim that PCV10,
which contains serotype 19F, provides cross-
protection effectiveness against serotype 19A,
Shiragami and colleagues referenced a case–
control study of invasive pneumococcal disease
in young children from Brazil by Domingues
and colleagues [30], in which only a few
numbers of discordant pairs supported their
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findings. Although the study design was robust,
the results are inconsistent with the national
surveillance system in Brazil, which shows an
increase in the incidence of serotype 19A
invasive pneumococcal disease between 2006
and 2011 in children younger than 5 years of
age [32, 33]. Domingues and colleagues
concluded that ‘‘Validation of this finding in
other settings is important because the point
estimate of effectiveness against serotype 19A
disease is higher than what might be expected
based on immunogenicity data, and the 95% CI
was wide. Additionally, PCV10 has not reduced
19A nasopharyngeal carriage in Kenya, where it
was introduced in early 2011’’. As another
example, in Finland, where PCV10 has been
used extensively, the incidence of serotype 19A
invasive pneumococcal disease continues to
rise, driven mostly by disease in older groups
[34]. In their analyses, Shiragami and colleagues
rely too heavily on the single, unsubstantiated
data point provided by the report of Domingues
and colleagues. Despite an initial case–control
study in the United States that demonstrated a
reduction in serotype 19A disease [35], real-
world experience confirms that PCV7 does not
provide cross-protection against serotype 19A
[36, 37]. Combined with the lack of
confirmation of any 19A cross-protection in
countries where PCV10 is used in a national
program [38, 39], it is inappropriate to use cross-
protection against 19A as a base case
assumption.
HERD EFFECTS
The analyses by Shiragami and colleagues do
not include any assumption regarding indirect
or herd effects. Herd effects are critical for
evaluating the full public health impact of
vaccines. Each case of pneumococcal disease
that is prevented indirectly provides an
economic and health benefit while imposing
no additional costs, making herd effects a
powerful driver of value. For PCV13, indirect
effects have been demonstrated and reported
for persons older than 5 years of age in
countries with pediatric immunization
programs and high vaccine uptake [13, 40].
This has not been the case for PCV10, as has
been clearly demonstrated in data from Finland
and Chile [41, 42].
SUMMARY
Because all important assumptions used in the
model are simultaneously biased toward PCV10,
the model results are erroneous and misleading.
Routine infant pneumococcal vaccination in
Japan would undoubtedly bring substantial
reductions in morbidity and mortality.
However, given the current epidemiologic
landscape in Japan and the current evidence,
the clinical and economic gains from the use of
PCV13 would, undoubtedly, far exceed those
potentially observed from the use of PCV10. We
urge those who conduct, critique, and consider
cost-effectiveness studies to evaluate the
strength of the evidence of clinical claims for
the products and the influence these
assumptions have on the overall findings. In
addition, when performing economic predictive
modeling, it is critical to provide a balanced
perspective by weighing the strengths and
weaknesses of all available data to construct
the base case analysis.
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